retatrutide trial results news for weight loss: Study shows 30% body weight loss Lilly's Retatrutide Scores Triple Trial

By product type, the injectable GLP-1 analogues segment held the biggest market share of 70% in 2025

Negative controls (omission of primary antibody) were used to confirm primary and secondary antibody specificity

Scalebar is 20 m

The peptide market has expanded rapidly, but not every supplier follows the same standards

In one of the studies, patients with a mean baseline body mass index (BMI) of 35.3 kg/m and an average HbA1c of 8.3% were randomized to receive varying doses of GLP-3 (ranging from 1 mg to 12 mg) or placebo over a 36-week study period

GZR18, a novel long-acting GLP-1 analog, demonstrated positive in vitro and in vivo pharmacokinetic and pharmacodynamic characteristics in animal models